ASND financial statements
The full income statement, balance sheet, and cash-flow statement for Ascendis Pharma A/S Ordinary Share (ASND), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 815M YoY+107.1% | 393M YoY+36.4% | 288M YoY+436.1% | 53.8M YoY+484.8% | 9.20M YoY+16.1% | |
708M YoY+104.7% | 346M YoY+43.7% | 240M YoY+485.8% | 41.0M YoY+715.5% | 5.03M YoY-36.5% | ||
| Research & development | 344M YoY+3.4% | 332M YoY-25.7% | 447M YoY+12.0% | 399M YoY+14.0% | 350M YoY+17.7% | |
| Operating income | -154M YoY+48.9% | -302M YoY+38.8% | -493M YoY+16.6% | -591M YoY-10.5% | -534M YoY-41.8% | |
| Interest expense | 234M YoY+116.1% | 108M YoY+127.1% | 47.7M YoY-10.2% | 53.1M YoY+1047.4% | 4.63M YoY-95.0% | |
| Pre-tax income | -241M YoY+40.4% | -404M YoY+21.2% | -513M YoY+15.6% | -608M YoY-33.8% | -454M YoY+5.0% | |
| Income tax | 17.4M YoY+232.2% | 5.24M YoY-33.6% | 7.90M YoY+39.7% | 5.65M YoY+1402.3% | -434K YoY-73.9% | |
-258M YoY+36.9% | -409M YoY+21.4% | -521M YoY+15.1% | -613M YoY-35.1% | -454M YoY+5.0% | ||
-$4.25 YoY+39.8% | -$7.07 YoY+23.6% | -$9.25 YoY+15.4% | -$10.93 YoY-32.1% | -$8.28 | ||
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
1.30B YoY+17.7% | 1.11B YoY+42.3% | 778M YoY-21.0% | 984M YoY+7.5% | 916M YoY+1.0% | ||
1.53B YoY+24.4% | 1.23B YoY+34.6% | 914M YoY-21.3% | 1.16B YoY-5.7% | 1.23B YoY+2.7% | ||
1.26B YoY+32.7% | 947M YoY+16.2% | 815M YoY+346.5% | 183M YoY+60.2% | 114M YoY+76.2% | ||
1.72B YoY+28.4% | 1.34B YoY+24.7% | 1.08B YoY+22.0% | 881M YoY+285.3% | 229M YoY+32.3% | ||
-191M YoY-73.5% | -110M YoY+31.6% | -161M YoY-157.4% | 281M YoY-72.0% | 1.00B YoY-2.3% | ||
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Cash from operations | 61.0M YoY+118.4% | -331M YoY+34.4% | -505M YoY+3.0% | -521M YoY-5.5% | -494M YoY-59.6% | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt issued | 0.00 YoY-100.0% | 145M YoY-1.5% | 147M YoY-72.2% | 529M | 0.00 | |
| Long-term debt repaid | 24.8M YoY+102.1% | 12.3M YoY+8.9% | 11.3M YoY+68.9% | 6.68M | 0.00 | |
| Common stock issued | 0.00 YoY-100.0% | 335M | 0.00 | 0.00 YoY-100.0% | 435M YoY-34.2% | |
| Common stock repurchased | 19.7M | 0.00 YoY-100.0% | 115M YoY+2.9% | 112M YoY+336.5% | 25.6M | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 13.2B YoY+58.2% | 8.36B YoY+16.1% | 7.20B YoY+3.5% | 6.95B YoY-9.2% | 7.66B YoY-14.6% | |
| P/S | 16.2× YoY-23.6% | 21.2× YoY-84.1% | 133.8× YoY-82.3% | 755.8× YoY-9.2% | 832.6× YoY-26.4% | |
| P/B | — | — | 25.6× YoY+270.1% | 6.9× YoY-9.2% | 7.6× YoY-12.5% | |
| Source filing | 20-F | 20-F | 20-F | 20-F | 20-F |
About this data
Source: ASND's SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn't file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all ASND filings on SEC EDGAR → Not investment advice.